Completed PHASE1 INTERVENTIONAL 3-arm NCT02328443

Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI (CYP3A_weak)

Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of Drug-drug Interaction in Korean Healthy Subjects

Sponsor: Seoul National University Hospital

Conditions Healthy

Interventions Midazolam itraconazole rifampicin

Updated 5 times since 2017 Last updated: Apr 15, 2016 Started: Jan 31, 2014 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02328443, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Seoul National University Hospital, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.